title: In silico experiment with an-antigen-toll like receptor-5 agonist fusion construct for immunogenic application to Helicobacter pylori.
abstract: BACKGROUND
  Helicobacter pylori colonize the gastric mucosa of half of the world's population. Although it is classified as a definitive type I carcinogen by World Health Organization, there is no effective vaccine against this bacterium. H. pylori evade the host immune response by avoiding toll-like detection, such as detection via toll-like receptor-5 (TLR-5). Thus, a chimeric construct consisting of selected epitopes from virulence factors that is incorporated into a TLR-5 ligand (Pseudomonas flagellin) could result in more potent innate and adaptive immune responses.
  
  
  METHODS
  Based on the histocompatibility antigens of BALB/c mice, in silico techniques were used to select several fragments from H. pylori virulence factors with a high density of B- and T-cell epitopes.
  
  
  RESULTS
  These segments consist of cytotoxin-associated geneA (residue 162-283), neutrophil activating protein (residue 30-135) and outer inflammatory protein A (residue 155-268). The secondary and tertiary structure of the chimeric constructs and other bioinformatics analyses such as stability, solubility, and antigenicity were performed. The chimeric construct containing antigenic segments of H. pylori proteins was fused with the D3 domain of Pseudomonas flagellin. This recombinant chimeric gene was optimized for expression in Escherichia coli. The in silico results showed that the conserved C- and N-terminal domains of flagellin and the antigenicity of selected fragments were retained.
  
  
  CONCLUSIONS
  In silico analysis showed that Pseudomonas flagellin is a suitable platform for incorporation of an antigenic construct from H. pylori. This strategy may be an effective tool for the control of H. pylori and other persistent infections.
authors.affiliation: Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
authors.forename: Mohamad Ali
authors.initials: MA
authors.lastname: Haghighi
authors.forename: Ashraf Mohabati
authors.initials: AM
authors.lastname: Mobarez
authors.forename: Ali Hatef
authors.initials: AH
authors.lastname: Salmanian
authors.forename: Mohamad
authors.initials: M
authors.lastname: Moazeni
authors.forename: Mohamad Reza
authors.initials: MR
authors.lastname: Zali
authors.forename: Mehdi
authors.initials: M
authors.lastname: Sadeghi
authors.forename: Jafar
authors.initials: J
authors.lastname: Amani
keywords: Cytotoxin-associated gene A; Helicobacter pylori; multi-epitope vaccine; neutrophil activating protein; outer inflammatory protein A
references.citation: Mol Immunol. 2005 May;42(8):879-85
references.pmid: 15829277
references.citation: Dig Liver Dis. 2009 Sep;41(9):634-8
references.pmid: 19261552
references.citation: Mol Immunol. 2008 May;45(9):2499-507
references.pmid: 18289677
references.citation: Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5186-91
references.pmid: 15795379
references.citation: Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16293-8
references.pmid: 17911250
references.citation: Braz J Microbiol. 2008 Jan;39(1):44-9
references.pmid: 24031176
references.citation: Gastroenterology. 2008 Jan;134(1):306-23
references.pmid: 18166359
references.citation: Expert Rev Vaccines. 2009 Aug;8(8):1037-49
references.pmid: 19627186
references.citation: Retrovirology. 2009 Jul 06;6:62
references.pmid: 19580659
references.citation: Infect Immun. 2008 Jan;76(1):334-8
references.pmid: 17967859
references.citation: Infect Immun. 2005 Nov;73(11):7151-60
references.pmid: 16239509
references.citation: J Immunol. 2001 Dec 15;167(12):7009-16
references.pmid: 11739521
references.citation: Helicobacter. 2009 Sep;14 Suppl 1:58-68
references.pmid: 19712170
references.citation: Cell Microbiol. 2007 Feb;9(2):290-9
references.pmid: 17284172
references.citation: FEBS Lett. 2006 May 22;580(12):2976-84
references.pmid: 16650409
references.citation: Vaccine. 2009 Sep 25;27(42):5875-84
references.pmid: 19654064
references.citation: Proteins. 2002 May 1;47(2):142-53
references.pmid: 11933061
references.citation: Curr Drug Targets Infect Disord. 2001 Nov;1(3):303-13
references.pmid: 12455403
references.citation: J Clin Invest. 2006 Apr;116(4):1092-101
references.pmid: 16543949
references.citation: J Exp Med. 2000 May 1;191(9):1467-76
references.pmid: 10790422
references.citation: Vaccine. 2009 Aug 6;27(36):5013-9
references.pmid: 19446591
references.citation: Nucleic Acids Res. 2009 Jul;37(Web Server issue):W277-80
references.pmid: 19435882
references.citation: Rev Gastroenterol Peru. 2009 Apr-Jun;29(2):158-70
references.pmid: 19609331
references.citation: Infect Immun. 2009 Sep;77(9):3782-90
references.pmid: 19546190
references.citation: Curr Opin Immunol. 2003 Aug;15(4):461-70
references.pmid: 12900280
references.citation: FEMS Immunol Med Microbiol. 2007 Jul;50(2):213-9
references.pmid: 17567282
references.citation: Helicobacter. 2008 Oct;13 Suppl 1:18-22
references.pmid: 18783517
references.citation: Infect Immun. 2003 Apr;71(4):1820-7
references.pmid: 12654796
references.citation: Immunol Lett. 2005 Nov 15;101(2):117-22
references.pmid: 15975666
references.citation: Microbes Infect. 2003 Dec;5(15):1345-56
references.pmid: 14670447
references.citation: Vaccine. 2007 Jan 8;25(4):763-75
references.pmid: 16968658
references.citation: World J Gastroenterol. 2009 May 21;15(19):2381-8
references.pmid: 19452583
references.citation: Vaccine. 2007 Jul 9;25(28):5155-65
references.pmid: 17548134
references.citation: Vaccine. 2004 Aug 13;22(23-24):3195-204
references.pmid: 15297074
references.citation: Cancer Lett. 2009 Sep 8;282(1):1-8
references.pmid: 19111390
references.citation: Immunol Lett. 1998 Nov;64(1):9-15
references.pmid: 9865596
references.citation: Infect Immun. 2006 Feb;74(2):1113-20
references.pmid: 16428759
references.citation: Int J Med Microbiol. 2008 Jan;298(1-2):27-32
references.pmid: 17888726
references.citation: J Infect Dis. 2004 May 15;189(10):1914-20
references.pmid: 15122529
references.citation: J Biol Chem. 2003 Jun 27;278(26):23624-9
references.pmid: 12711596
references.citation: Mayo Clin Proc. 2008 Feb;83(2):169-75
references.pmid: 18241627
references.citation: Microb Pathog. 2008 Jan;44(1):20-7
references.pmid: 17683897
references.citation: PLoS One. 2009;4(4):e5383
references.pmid: 19401783
references.citation: FEMS Immunol Med Microbiol. 2007 Jul;50(2):157-64
references.pmid: 17521355
references.citation: Theor Biol Med Model. 2009 Dec 08;6:28
references.pmid: 19995413
references.citation: Vaccine. 2005 Mar 18;23(17-18):2121-31
references.pmid: 15755582
references.citation: Int J Mol Med. 2005 Jul;16(1):165-71
references.pmid: 15942694
references.citation: J Immunol Methods. 2004 Feb 1;285(1):93-7
references.pmid: 14871538
references.citation: Nat Immunol. 2006 Oct;7(10):1029-35
references.pmid: 16985500
references.citation: PLoS One. 2008 Oct 02;3(10):e3307
references.pmid: 18830403
references.citation: Protein Sci. 2006 Nov;15(11):2558-67
references.pmid: 17001032
references.citation: J Infect Dis. 2006 Nov 15;194(10):1346-55
references.pmid: 17054063
references.citation: Vaccine. 2001 Sep 14;19(32):4883-95
references.pmid: 11535342
references.citation: Methods Enzymol. 1996;266:540-53
references.pmid: 8743705
references.citation: J Biol Chem. 2004 Feb 13;279(7):5667-75
references.pmid: 14634022
references.citation: Int Arch Allergy Immunol. 2002 Mar;127(3):245-50
references.pmid: 11979050
references.citation: J Formos Med Assoc. 2008 Aug;107(8):591-9
references.pmid: 18678542